Humacyte (HUMA) said Acellular Tissue Engineered Vessel or ATEV has been granted the FDA's Regenerative Medicine Advanced Therapy designation for patients with advanced peripheral artery disease. It was previously announced that, the common name Acellular Tissue Engineered Vessel or ATEV replaced the term Human Acellular Vessel or HAV previously used for the engineered vessel product candidate.
The ATEV is an investigational product and has not been approved for sale by any regulatory agency. The company noted that the designation allows for close interactions with the FDA and potentially an expedited/priority review of a Biologics License Application.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.